...
search icon
kmda-img

Kamada, Common Stock

KMDA

NSQ

$7.63

-$0.2

(-2.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$438.67M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
29
Volume info-icon
This is the total number of shares traded during the most recent trading day.
147.21K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.24
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.74 L
$9.15 H
$7.63

About Kamada, Common Stock

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKMDASectorS&P500
1-Week Return-4.03%0.54%0.54%
1-Month Return7.77%3.28%1.66%
3-Month Return31.1%3.01%3.83%
6-Month Return35.77%-4.69%9.77%
1-Year Return26.01%1.41%23.47%
3-Year Return33.39%15.72%42.73%
5-Year Return24.07%42.38%82.01%
10-Year Return66.96%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue127.19M133.25M103.64M129.34M142.52M[{"date":"2019-12-31","value":89.24,"profit":true},{"date":"2020-12-31","value":93.49,"profit":true},{"date":"2021-12-31","value":72.72,"profit":true},{"date":"2022-12-31","value":90.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue77.45M85.69M73.31M82.64M87.03M[{"date":"2019-12-31","value":88.99,"profit":true},{"date":"2020-12-31","value":98.47,"profit":true},{"date":"2021-12-31","value":84.24,"profit":true},{"date":"2022-12-31","value":94.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit49.74M47.55M30.33M46.70M55.49M[{"date":"2019-12-31","value":89.63,"profit":true},{"date":"2020-12-31","value":85.69,"profit":true},{"date":"2021-12-31","value":54.65,"profit":true},{"date":"2022-12-31","value":84.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin39.11%35.69%29.26%36.11%38.94%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.26,"profit":true},{"date":"2021-12-31","value":74.83,"profit":true},{"date":"2022-12-31","value":92.34,"profit":true},{"date":"2023-12-31","value":99.56,"profit":true}]
Operating Expenses26.95M28.32M31.02M42.17M45.43M[{"date":"2019-12-31","value":59.33,"profit":true},{"date":"2020-12-31","value":62.33,"profit":true},{"date":"2021-12-31","value":68.3,"profit":true},{"date":"2022-12-31","value":92.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income22.78M19.24M(401.00K)(1.64M)10.06M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":84.43,"profit":true},{"date":"2021-12-31","value":-1.76,"profit":false},{"date":"2022-12-31","value":-7.21,"profit":false},{"date":"2023-12-31","value":44.17,"profit":true}]
Total Non-Operating Income/Expense1.05M89.00K(2.17M)(7.61M)(2.35M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.48,"profit":true},{"date":"2021-12-31","value":-206.76,"profit":false},{"date":"2022-12-31","value":-725.14,"profit":false},{"date":"2023-12-31","value":-223.33,"profit":false}]
Pre-Tax Income22.98M18.57M(1.89M)(2.26M)8.43M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":80.78,"profit":true},{"date":"2021-12-31","value":-8.2,"profit":false},{"date":"2022-12-31","value":-9.83,"profit":false},{"date":"2023-12-31","value":36.68,"profit":true}]
Income Taxes730.00K1.43M345.00K62.00K145.00K[{"date":"2019-12-31","value":51.23,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":24.21,"profit":true},{"date":"2022-12-31","value":4.35,"profit":true},{"date":"2023-12-31","value":10.18,"profit":true}]
Income After Taxes22.25M17.14M(2.23M)(2.32M)8.28M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.03,"profit":true},{"date":"2021-12-31","value":-10.02,"profit":false},{"date":"2022-12-31","value":-10.43,"profit":false},{"date":"2023-12-31","value":37.23,"profit":true}]
Income From Continuous Operations22.25M17.14M(2.23M)(2.32M)8.28M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.03,"profit":true},{"date":"2021-12-31","value":-10.02,"profit":false},{"date":"2022-12-31","value":-10.43,"profit":false},{"date":"2023-12-31","value":37.23,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income22.25M17.14M(2.23M)(2.32M)8.28M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.03,"profit":true},{"date":"2021-12-31","value":-10.02,"profit":false},{"date":"2022-12-31","value":-10.43,"profit":false},{"date":"2023-12-31","value":37.23,"profit":true}]
EPS (Diluted)0.540.39(0.05)(0.05)0.15[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":72.22,"profit":true},{"date":"2021-12-31","value":-9.26,"profit":false},{"date":"2022-12-31","value":-9.26,"profit":false},{"date":"2023-12-31","value":27.78,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KMDA
Cash Ratio 2.12
Current Ratio 4.84
Quick Ratio 2.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KMDA
ROA (LTM) 3.22%
ROE (LTM) 6.37%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KMDA
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KMDA
Trailing PE 29.00
Forward PE 25.19
P/S (TTM) 2.84
P/B 1.76
Price/FCF 22
EV/R 2.43
EV/Ebitda 13.18
PEG 8.75

FAQs

What is Kamada share price today?

Kamada (KMDA) share price today is $7.63

Can Indians buy Kamada shares?

Yes, Indians can buy shares of Kamada (KMDA) on Vested. To buy Kamada from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KMDA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kamada be purchased?

Yes, you can purchase fractional shares of Kamada (KMDA) via the Vested app. You can start investing in Kamada (KMDA) with a minimum investment of $1.

How to invest in Kamada shares from India?

You can invest in shares of Kamada (KMDA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KMDA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kamada shares
What is Kamada 52-week high and low stock price?

The 52-week high price of Kamada (KMDA) is $9.15. The 52-week low price of Kamada (KMDA) is $4.74.

What is Kamada price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kamada (KMDA) is 29

What is Kamada price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kamada (KMDA) is 1.76

What is the Market Cap of Kamada?

The market capitalization of Kamada (KMDA) is $438.67M

What is Kamada’s stock symbol?

The stock symbol (or ticker) of Kamada is KMDA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top